

# On track to deliver 2021 financial targets

Meeting the Management

Michael Pontzen, CFO

# In 2017 we set our 2021 financial targets in a favorable market environment

Despite rising political risks, global economy was robust

## 2017



Asia and USA with strong growth, Brazil recovery expected



Additional US growth foreseeable due to pending tax reform



Main customer industries expected to continue a growth path

|  | 2016   | What we aim for (~2021) |
|--|--------|-------------------------|
| <b>EBITDA pre margin</b><br>(group, Ø through the cycle) | 10-14% | <b>14-18%</b>           |
| <b>EBITDA margin volatility</b>                          | MEDIUM | LOW<br><b>2-3%pts</b>   |
| <b>Cash Conversion*</b>                                  | 56%    | <b>&gt;60%</b>          |

\* Cash Conversion = EBITDA pre – CAPEX / EBITDA pre

# In 2019 the world is much more challenging, but we are well on track to achieve our goals

The political uncertainty with full negative impact on global economy

## 2019



Asian economies with visible slowdown, Brasil recovery pending, LATAM uncertain



Serious trade conflicts / BREXIT



Main customer industries weak, auto in crisis mode, capital goods and agro sluggish

**EBITDA pre margin**  
(group, Ø through the cycle)

**EBITDA margin volatility**

**Cash Conversion**

## We stick to our targets (~2021)

**Specialty level**

**Resilience**

**Strong cash generation**


# LANXESS self-help measures are the foundation on our way to achieve our financial targets

Active portfolio management

Significantly reduced auto exposure

More balanced regional exposure

Profitable organic growth



Leveraging of synergies



Streamlining asset network

Additional organic growth with ROCE ~20%

Further M&A and restructuring

# LANXESS margin improvement and resilience proven

**Stable margin growth in cyclical environment**  
**Margin resilience proven in recent quarters!**





\* European Peers: Arkema, DSM, Covestro, BASF, Clariant, Evonik, Solvay

# Cash Conversion target also on track – but at what price does it come?

We could deliver on our Cash Conversion target already in 2019, but give priority to profitable growth

2019 estimate in € m



\* Cash Conversion = EBITDA pre – CAPEX / EBITDA pre; \*\* ROCE: ~ 20%, considering ~€10 m D&A & ~30% tax

# We decided to invest ~€400 m in financially attractive debottleneckings and brownfield investments



**Advanced Intermediates**



**Specialty Additives**



**Performance Chemicals**



**Engineering Materials**



*Targeted growth CAPEX until 2020, in € m*

**~150**

**~50 - 100**


**~50 - 100**

**~50 - 100**



# Organic investments fuel improvement of ROCE\*

**Adjusted ROCE\* shows improved operational return profile of LANXESS**



**Transformation pays off:**


- Divestment of ARLANXEO
- Acquisition of Chemtura
- Streamlining asset network
- Organic growth investments

\* Adjusted ROCE = EBIT pre adjusted for amortization of Chemtura PPA related intangibles & assumed ARL ROCE



# Strong management attention also on EPSpre\*

## Strong EPSpre\* growth



## Active EPS management:

- Operational improvement
- Lower interest expenses
- Funding of pension debt
- Tax management (tax rate from ~45% to ~30% in 2019)
- Share buyback in 2019

\* Earnings per Share: net of exceptionals and amortization of intangible assets as well as attributable tax effects / figures for 2014 until 2016 exclude ARLANXEO (non audited figures)

# Capital allocation follows shareholder interests

Shareholder return is the driver for capital allocation

*illustrative*  
(€ m)

~1000



EBITDApre

~120



~300 - 350

Tax

Maintenance  
CAPEX

~550



Free Cash  
Flow



Organic growth



Restructuring



Mergers & Acquisitions



Share buyback



Dividend



Deleveraging



Interest expenses

# Our project pipeline allows us to continue our organic growth path

We keep our internal benchmark for organic growth projects: 20% ROCE

*Growth CAPEX from 2021, examples*



**Advanced Industrial Intermediates**  
Aromatics ~€100 m




**Performance Chemicals**  
Biocides, Resins ~€50 m



**High Performance Materials**  
TEPEX, Resins  
~€50 -100 m



**Polymer Additives**  
Lithium ~€100 – 400 m



## Future invest approach:

- Attractive ROCE around 20%
- Focus on debottlenecking and brownfield investments
- Strategic fit to future growth markets
- Strengthen regional presence or balance growth regions



# Tepex: Leveraging strong demand for continuous fiber reinforced thermoplastics

Thermoplastic composite sheets serve as powerful and cost effective substitute for traditional components




~€40 m  
Investment



1H 2022  
Planned operation start



Illustrative: Tepex adressable global market volume\*



# LANXESS strengthens its All aromatic „Verbund“ with additional synthetic menthol capacity

Clear long-term investment approach based on synergetic customer relationship



~€40 m

Investment



Early 2021

Planned operation start

## Investment rationale:

- Significant increase in demand for synthetic menthol
- Strong customer relation based on long-term contracts
- Downstream development of the aromatic „Verbund“



# Venture investment into Lithium with low risk and potentially high return

Opportunity in cooperation with Standard Lithium



~€100 –  
400 m  
Investments





Early 2021  
Planned start of  
construction

## Investment rationale:

- Potential lucrative yield of battery grade lithium from LANXESS' „waste material“ tail brine
- Strong growth of Lithium use based on rising demand for batteries



# The journey will continue ...



\* European Peers: Arkema, DSM, Covestro (formerly BMS), BASF, Clariant, Evonik, Solvay

# Looking ahead ... energized!

## Profitability

**Moving our way towards even more stable and attractive margin levels**

## Resilience

**Further balanced exposure to end markets and regions in the future**

## Financials

**Maintaining strong financials and balanced debt**

## Rating

**Commitment to stay solid investment grade**

